4 October 2024
La Vie closes €25 million fundraising round
Watch the replay of Good Morning Business, on BFM Business with interviews with Nicolas Schweitzer, co-founder of La Vie ™, a company in our HFL portfolio, interviewed by...
All
3 October 2024
Citryll and leading rheumatology centres receive Reumanederland grant to collaborate on NET research to advance novel treatments for rheumatoid arthritis.
Citryll, a clinical-stage biotech company developing first-inclass therapeutics to treat immune-mediated inflammatory diseases, today announces a groundbreaking collaboration...
24 September 2024
Sequentia Biotech Secures €10million Equity Investment from Seventure Partners and the EIC Fund to Boost Bioinformatic Solutions for Clinical, Industrial and Research Applications
Sequentia Biotech, a #deeptech and leading bioinformatics company focused on the analysis and application of omics data, announces a €10million Series A, led by Seventure...
23 September 2024
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group Announce New Collaboration Agreement
The European Microbiome Innovation for Health (EMIH) association today announced an agreement between the Microbiome Therapeutics Innovation Group (MTIG) and EMIH for a...
28 August 2024
Water recycling: Chemdoc Water Technologies boosts its financial resources
4.5 million euros. On July 10, Chemdoc Water Technologies, a small business in the Herault region specializing in the manufacture of equipment for the treatment of industrial...
27 August 2024
Microbiotica’s Microbiome Medicines in Melanoma and Ulcerative Colitis Gain Regulatory Approvals in EU and UK for Phase 1b Studies
Microbiotica’s Microbiome Medicines in Melanoma and Ulcerative Colitis Gain Regulatory Approvals in EU and UK for Phase 1b Studies
Company Secures Additional Financing...
21 August 2024
Biotech: why Singapore’s Allozymes is setting up its European subsidiary in Toulouse
Allozymes, a leading innovator in the discovery and engineering of enzymes (proteins acting as catalysts in all living organisms) for the food and chemical industries, has...
5 August 2024
Fierce Biotech Names Tubulis a “Fierce 15” Biotech Company of 2024
Tubulis announced today that Fierce Biotech has named the company as one of 2024’s “Fierce 15” biotechnology companies. The annual special report features the most...
31 July 2024
CITRYLL ANNOUNCES COMPLETION OF PATIENT ENROLMENT AND DOSING IN THE REPEAT DOSING STAGE OF THE PHASE 1 TRIAL FOR THE NOVEL ANTI-INFLAMMATORY DRUG, CIT-013
Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announces the successful completion of...
27 June 2024
Tubulis Receives FDA Fast Track Designation for Antibody-Drug Conjugate Candidate TUB-040 in Platinum-resistant Ovarian Cancer
Tubulis announced today that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to its lead antibody-drug conjugate (ADC) TUB-040 for the...